Sandoz, UTC Settle Generic Remodulin Patent Suit
United Therapeutics Corp. has given Sandoz Inc. a non-exclusive license to manufacture and sell a generic version of its hypertension drug Remodulin, ending more than three years of patent litigation, UTC...To view the full article, register now.
Already a subscriber? Click here to view full article